Burwell Cautions Against Changing FDA Standards, Recommends Cybersecurity Investment
Executive Summary
As one potential candidate for FDA commissioner has called for dismissing efficacy requirements to approve products, Burwell, soon before relinquishing her role as HHS secretary, told reporters that safety trials are insufficient to prove true safety and that her successor at HHS should prioritize cybersecurity.
You may also be interested in...
Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking
O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.
Massive Family Dollar Rat Infestation Leads To Multi-State Recall
The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.
Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.